VIDAC PHARMA HOLDING PLC
Commented by Nico Popp on July 25th, 2025 | 07:00 CEST
Key technology in the fight against cancer? Merck & Co., Vidac Pharma, AstraZeneca
Do you know what aerobic glycolysis is? No? Have you ever heard of the Warburg effect? Both terms describe the same phenomenon: cancer cells utilize glucose to produce lactate, even in the presence of oxygen and fully functional mitochondria. This is what distinguishes cancer cells from healthy cells. Current research suggests that targeted interventions in the Warburg effect could be suitable for killing cancer cells or making them more receptive to other therapies. Companies around the world are pushing forward research into this effect – the goal is nothing less than curing cancer. We present some of the companies and analyze whether their stocks could be good investments.
Read
Commented by André Will-Laudien on July 14th, 2025 | 07:25 CEST
DAX correction! Biotech in takeover mode! BioNTech, CureVac, Pfizer, Vidac Pharma, and Kraft Heinz in focus
The stock markets are in top form: both the DAX and the NASDAQ 100 have flexed their muscles in recent days. Prices are being driven primarily by the continued strength of technology stocks and growing hopes for stable global economic growth, despite Donald Trump's tariff madness. At the same time, a growing takeover fever in the biotechnology sector is providing additional momentum. In the field of cancer research in particular, companies such as BioNTech, Moderna, and other specialized mRNA players such as CureVac are increasingly becoming the focus of strategic investors. The fight against cancer is increasingly becoming one of the key drivers for new partnerships and market consolidation. Speculation about possible mergers and billion-dollar acquisitions is currently on the rise again. This opens up an exciting environment for investors, offering opportunities for above-average returns. We identify the trigger points.
Read
Commented by Armin Schulz on July 9th, 2025 | 07:05 CEST
Liver cancer breakthrough fuels billion-dollar market: How Bayer, Vidac Pharma, and Novo Nordisk can now power your portfolio
The pharmaceutical industry is undergoing its biggest upheaval in decades. Megatrends such as cancer treatment, fueled by recent breakthroughs like the EMA approval of the liver cancer therapy Lenvima®/Keytruda®, and revolutionary therapies for diabetes and obesity are generating billion-dollar markets. Those who understand these growth drivers will identify lucrative opportunities. Innovative active ingredients are not only changing medicine but also unlocking exceptional return potential for forward-thinking investors. This dynamic draws attention directly to the strategies of Bayer, Vidac Pharma, and Novo Nordisk.
Read
Commented by Nico Popp on July 4th, 2025 | 07:10 CEST
Biotech stocks with a safety net and double bottom: Vidac Pharma, BioNTech, and Gilead Sciences
For many years, biotech stocks were considered speculative bets on a single, all-important active ingredient. For seasoned biotech investors, it was once clear that there was little gray area between multiplication and total loss. But the biotech landscape has changed. Innovative technologies and modern processes ensure that even smaller biotech companies have several arrows in their quiver that can hit the mark. We explain what has changed in the biotech sector and what opportunities for collaboration could exist between BioNTech, Gilead Sciences, and Vidac Pharma.
Read
Commented by Fabian Lorenz on June 25th, 2025 | 07:30 CEST
BioNTech swallows CureVac! Evotec and Vidac Pharma next? Price driver takeover and Buy recommendation
Is Vidac Pharma about to see another price explosion? Last fall, the share rose by around 200%. Yesterday, there was a "Buy" recommendation. Analysts see potential for growth in this biotech gem. The latest news on the drug candidate VDA 1102 for brain tumors is promising. Could a takeover be on the cards? CureVac's share price has nearly doubled since the beginning of April. BioNTech plans to acquire its mRNA competitor and thus end patent disputes. Evotec is a permanent fixture on the takeover merry-go-round. However, this currently seems to be the only hope for rising share prices. The management's new strategy has not created the hoped-for wave of optimism. Is it still worth buying now?
Read
Commented by André Will-Laudien on June 19th, 2025 | 07:00 CEST
Biotech: Weight loss and cancer – Takeovers ahead! Keep an eye on Evotec, Vidac Pharma, Eli Lilly, and Novo Nordisk!
For nearly two years, the biotech sector remained largely stagnant. But in the last few weeks, some heavily bombed-out life science stocks have seen significant gains, and takeovers are back on the agenda. Eli Lilly is acquiring Verve Therapeutics, and BioNTech has finally reached an agreement with CureVac. The carousel is slowly starting to turn, and tensions are rising. New rumors are circulating, especially as major pharma stocks like Eli Lilly and Novo Nordisk are showing negative 12-month performance - despite record highs in the major indices.
What is next?
Commented by Armin Schulz on June 2nd, 2025 | 07:10 CEST
Bayer, Vidac Pharma, Evotec – Grab your share of the USD 866 billion oncology jackpot
Oncology is undergoing an unprecedented revolution. With a projected market volume of USD 866 billion by 2034 and annual growth of 11%, AI-driven diagnostics, personalized gene therapies, and precision medicine are driving this boom. Rising disease rates worldwide are fueling investment, while technological leaps are making therapies more effective and opening up high-return opportunities. Three players aim to leverage this explosive momentum for their profitable future: Bayer, Vidac Pharma, and Evotec.
Read
Commented by Fabian Lorenz on May 29th, 2025 | 07:10 CEST
Rheinmetall unstoppable! Evotec shorted! Sensational news at Vidac Pharma! And what is BioNTech doing?
Sensational news at Vidac Pharma. Last year's biotech highflyer has published strong results for its cancer drug. The share price rose by 5% yesterday. Does this mean the consolidation is over? Analysts certainly see potential for a multiplication in value. Rheinmetall shares have gained over 200% this year alone. Analysts are raising their price targets and continue to recommend buying. Operationally, a lot is happening at the defense company. Meanwhile, Evotec has run out of steam operationally. The stock has become a plaything for takeover speculators and short sellers — who will win? BioNTech also wants to win the fight against cancer. Will the stock gain new momentum in the coming days?
Read
Commented by André Will-Laudien on May 20th, 2025 | 07:10 CEST
Where will the biotech winner of 2025 come from? Evotec, Bayer, BioNTech, Vidac Pharma, and Pfizer under stock review
With new announcements coming out of Washington daily, the stock market carousel is spinning faster and faster. The direction is no longer uniformly upward, but deeper corrections, such as those seen in April, offer good entry opportunities. While the DAX 40 index reached a new all-time high yesterday at 23,977 points and has already recorded 27% growth in 2025, the Nasdaq Biotech Index (NBI) has lost a full 7.2% over the past six months. We have examined several interesting sector players and identified both opportunities and risks. In short, careful selection is once again key!
Read
Commented by Nico Popp on May 13th, 2025 | 07:10 CEST
The fight against cancer as a billion-dollar opportunity: BioNTech, Merck, and Vidac Pharma
Cancer is the scourge of our time. However, significant progress has already been made in recent years. In addition to significantly improved traditional therapies, individualized treatment approaches such as immunotherapy are repeatedly proving successful in curing patients. This trend is set to continue. Experts such as the investors at Candriam and market researchers at Spherical Insights foresee enormous growth – the market for cancer drugs could see double-digit annual growth by the 2030s. Market leaders such as BioNTech and Merck, as well as insider tips like Vidac Pharma, stand to benefit.
Read